Header Logo

Connection

MICHAEL ITTMANN to Immunohistochemistry

Back to Details
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Immunohistochemistry.
MICHAEL ITTMANN
Connection Strength
0.863
Immunohistochemistry
  1. Comparative analysis of p16 expression among African American and European American prostate cancer patients. Prostate. 2019 08; 79(11):1274-1283.
    View in: PubMed
    Score: 0.117
  2. Oxidative stress promotes benign prostatic hyperplasia. Prostate. 2016 Jan; 76(1):58-67.
    View in: PubMed
    Score: 0.091
  3. Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87.
    View in: PubMed
    Score: 0.089
  4. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 2006 Jun 01; 66(8):847-57.
    View in: PubMed
    Score: 0.048
  5. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6169-78.
    View in: PubMed
    Score: 0.042
  6. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004 Jul 15; 64(14):4728-35.
    View in: PubMed
    Score: 0.042
  7. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate. 2003 Apr 01; 55(1):30-8.
    View in: PubMed
    Score: 0.038
  8. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001 Dec; 159(6):2159-65.
    View in: PubMed
    Score: 0.035
  9. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology. 2020 Dec; 77(6):890-899.
    View in: PubMed
    Score: 0.032
  10. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res. 2000 Aug 01; 60(15):4245-50.
    View in: PubMed
    Score: 0.032
  11. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol. 1999 Apr; 30(4):419-24.
    View in: PubMed
    Score: 0.029
  12. Cellular interactions of the phosphorylated form of AKT in prostate cancer. Hum Pathol. 2017 05; 63:98-109.
    View in: PubMed
    Score: 0.025
  13. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.025
  14. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol. 1996 Jan; 27(1):28-34.
    View in: PubMed
    Score: 0.023
  15. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015 Jun; 6(2-3):67-86.
    View in: PubMed
    Score: 0.022
  16. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol. 1994 Aug; 145(2):287-93.
    View in: PubMed
    Score: 0.021
  17. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011 Dec 15; 71(24):7694-704.
    View in: PubMed
    Score: 0.017
  18. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.016
  19. TGF-?1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. PLoS One. 2010 Oct 29; 5(10):e13751.
    View in: PubMed
    Score: 0.016
  20. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 2010 Aug 13; 285(33):25859-66.
    View in: PubMed
    Score: 0.016
  21. Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX. J Clin Virol. 2009 Oct; 46(2):154-60.
    View in: PubMed
    Score: 0.015
  22. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.014
  23. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007 Dec; 12(6):559-71.
    View in: PubMed
    Score: 0.013
  24. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol. 2007 Feb; 38(2):299-307.
    View in: PubMed
    Score: 0.012
  25. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.012
  26. Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate. 2004 Jan 01; 58(1):1-12.
    View in: PubMed
    Score: 0.010
  27. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003 May 15; 55(3):219-37.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.